Search Bar & Filters
Found 27 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenously administered YN001 in adults diagnosed with coronary atherosclerosis who are also receiving treatment for cardiovascular risk factors. This multinational, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial aims to compare different doses of YN001 with placebo in this population. Participants will be randomly assigned to receive one of three weekly intravenous treatments YN001 at 40mg, YN001 at 20mg, or a placebo at 0mg. Treatment will be administered once weekly for 13 weeks, totaling 13 doses. The study includes a screeningbaseline period lasting up to 12 weeks, a 12-week blinded treatment phase, followed by a 30-day safety follow-up and a long-term monitoring period lasting approximately 2 years after randomization. During the study, participants will undergo various assessments including imaging scans to measure changes in coronary and carotid artery plaque, blood tests to analyze YN001 concentration and immune responses, and monitoring for major adverse cardiac events. The primary measurement is the relative change in coronary non-calcified plaque volume from baseline to week 13. Safety and immune response will be closely tracked throughout treatment and follow-up, with total participation lasting up to about 2 years.
Actively Recruiting
Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.
Actively Recruiting
Researchers are evaluating how CDR132L, a potential new medicine, affects the structure and function of the heart in people living with heart failure. The study focuses on individuals with preserved ejection fraction and left ventricular hypertrophy. It is a phase 2, randomized, double-blind, placebo-controlled trial aimed at assessing the safety and efficacy of CDR132L on reversing cardiac remodeling. Participants will be randomly assigned to receive one of three different doses of CDR132L or a placebo. All treatments are given as intravenous infusions once every 4 weeks for 48 weeks. Throughout the study, participants will continue their individually tailored guideline-directed standard care therapy for heart failure. The trial duration is about 60 weeks. During the study, participants will undergo various assessments, including measuring changes in microRNA-132 levels as the primary outcome at 24 weeks. Secondary outcomes include changes in heart structure measured by cardiac magnetic resonance imaging and blood biomarkers, as well as monitoring adverse events up to 60 weeks. Participants will receive regular infusions and attend scheduled visits for monitoring and safety evaluations.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.
Actively Recruiting
Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.
Actively Recruiting
Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.
1-10 of 27
1